NEW YORK (GenomeWeb News) – Sequenom today said second-quarter net loss narrowed on a 15-percent increase in revenues and reduced R&D spending.
 
The results caused shares in the company to trade up 6.9  percent, or $.11, at $1.70 mid-afternoon today.
 
Receipts for the three months ended June 30 increased to $7 million from $6 million year over year.
 
R&D costs declined almost 20 percent to $2.4 million from $3 million from the comparable quarter a year ago.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.